Innoviva (INVA) Cash & Equivalents (2010 - 2026)

Innoviva's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $603.1 million for Q1 2026.

• Quarterly Cash & Equivalents rose 89.0% year-over-year to $603.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $603.1 million (up 89.0% YoY) and the FY2025 annual result came in at $550.9 million, up 80.66% from the prior year.
• Cash & Equivalents was $603.1 million for Q1 2026 at Innoviva, up from $550.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $603.1 million in Q1 2026 and bottomed at $144.0 million in Q1 2023.
• A 5-year average of $299.5 million and a median of $283.6 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 555.45% — and 2023, when it sank 40.16%.
• Innoviva's Cash & Equivalents stood at $291.0 million in 2022, then tumbled by 33.51% to $193.5 million in 2023, then surged by 57.59% to $305.0 million in 2024, then surged by 80.66% to $550.9 million in 2025, then climbed by 9.46% to $603.1 million in 2026.
• Business Quant data shows INVA's Cash & Equivalents at $603.1 million in Q1 2026, $550.9 million in Q4 2025, and $476.5 million in Q3 2025.